Their downregulation, often via promoter hypermethylation, leads to excessive activation of hepatocyte growth factor/c-MET or protease-activated receptor-2/NF-κB signaling, promoting epithelial-mesenchymal transition and cancer progression. The gene discussed is HGF; the disease is cancer.